Clinical Trials Logo

Dermatitis, Allergic Contact clinical trials

View clinical trials related to Dermatitis, Allergic Contact.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05339750 Completed - Clinical trials for Allergic Contact Dermatitis

Allergy Skin Patch Artificial Intelligence (AI)

Start date: February 15, 2022
Phase: N/A
Study type: Interventional

The purpose of this research is to assess human and artificial intelligence performance in grading contact dermatitis reactions in healthy volunteers.

NCT ID: NCT04921163 Completed - Contact Dermatitis Clinical Trials

Children With Aluminium Contact Allergy: Oral Exposure Study

Start date: June 1, 2021
Phase: N/A
Study type: Interventional

Aluminium allergy is predominantly seen in children with small itchy nodules in the skin after vaccinations, so-called granulomas. We want to do an exposure study where aluminium allergic children have to eat aluminium pancakes for a short period of time. The purpose is to investigate whether a worsening of the children's symptoms can be detected, both itching of the granuloma, allergic rash on the skin and also the symptoms that are not measurable, such as headache, stomach ache and general agitation. We also want to examine the concentration of aluminium in the urine, which reflects the absorption of aluminum from the gastrointestinal tract.

NCT ID: NCT04438135 Completed - Contact Dermatitis Clinical Trials

Children With Aluminium Contact Allergy: Cutaneous Exposure Study

Start date: June 10, 2020
Phase: N/A
Study type: Interventional

Aluminium is used in many different cosmetic products, including make-up, deodorants and sunscreen. The purpose of this study is to investigate whether these everyday skin products with small amounts of aluminium can cause skin reactions in children diagnosed with contact allergy to aluminium. The study is conducted as a Repeated Open Application Test study (ROAT), a method originally developed to clarify the clinical relevance of questionable and positive patch samples, by imitating everyday use of a skin product.

NCT ID: NCT04365140 Completed - Clinical trials for Allergic Contact Dermatitis

MicroRNA-126 and Its Target VCAM-1Dermatitis to Nickel

Start date: March 1, 2019
Phase:
Study type: Observational [Patient Registry]

Background. Allergic Contact Dermatitis (ACD) is an inflammatory skin disease mediated by direct contact with allergens as nickel, the most common allergen, that may be related with epigenetic changes. Objective. Evaluate the miR-126 expression and its target VCAM-1, in the skin of patients with ACD to nickel. Methods. Fifteen patients with positive patch test to nickel were included, and the expression of miR-126 and VCAM-1 was evaluated by RT-qPCR.

NCT ID: NCT04182425 Completed - Infectious Diseases Clinical Trials

Incidence of Allergic Manifestations and Infectious Episodes in Healthy Term Infants at Risk for Dysbiosis

SOPRANO
Start date: December 7, 2019
Phase:
Study type: Observational [Patient Registry]

This study will evaluate the incidence of allergic manifestations (the first of which is atopic dermatitis) and infectious diseases in children fed with an infant formula under real conditions of use.

NCT ID: NCT03945760 Completed - Clinical trials for Allergic Contact Dermatitis

Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects

Start date: September 14, 2020
Phase: Early Phase 1
Study type: Interventional

The treatment of allergic contact dermatitis (ACD) can be unsatisfactory, and that other skin diseases such as atopic dermatitis have an increased likelihood of ACD, improved systemic treatments are needed. This research study explores the effectiveness of Baricitinib in treating Delayed-Type Hypersensitivity (allergic) versus Irritant Skin reactions. Subjects for this study need to be healthy males between the ages of 18 and 40. This study will evaluate this by injecting antigens as well as applying them on top of the skin to the forearm then measure the effects of Baricitinib by skin and blood testing.

NCT ID: NCT03902392 Completed - Clinical trials for Allergic Contact Dermatitis

Red Grape Polyphenol Oral Administration to Women Affected by Nickel-mediated Allergic Contact Dermatitis

Grapolyphen
Start date: April 16, 2018
Phase: N/A
Study type: Interventional

Nickel (Ni)-mediated allergic contact dermatitis (ACD) is a very common disease worldwide. Our previous findings demonstrated that in vitro supplementation of polyphenols, extracted from seeds of red grape (Nero di Troia cultivar), to peripheral lymphomonocytes from Ni-mediated ACD patients could reduce release of T helper (h)1 [interferon (IFN)-] and Th2 [interleukin (IL)-4] cytokines, on the one hand. On the other hand, IL-10 (an anti-inflammatory cytokine) levels increased with a reduction of IL-17 (an inflammatory cytokine). Also levels of nitric oxide (NO) decreased in response to polyphenol pretreatment.

NCT ID: NCT03522675 Completed - Allergy Clinical Trials

NeoMatriX Wound Matrix Collagen Dressing Skin Prick Test

Start date: April 11, 2018
Phase: N/A
Study type: Interventional

The objective of this study is to investigate the potential of NeoMatriXTM Wound Matrix to cause an allergic response to healthy volunteers using a skin prick test.

NCT ID: NCT03474874 Completed - Allergy Clinical Trials

Human Repeated Insult Patch Test

Start date: February 26, 2018
Phase: N/A
Study type: Interventional

Repeated insult patch test on healthy males and females to determine potential contact irritation or contact allergy in the skin

NCT ID: NCT03313232 Completed - Clinical trials for Allergic Contact Dermatitis Due to Cosmetics

Low Dose Exposure to Oxidized R-limonene - A Repeated Open Application Test (ROAT) Study

Start date: October 10, 2017
Phase: N/A
Study type: Interventional

This study evaluates the clinical and molecular effect of daily exposure to low doses of the fragrance contact allergen oxidized R-limonene. Three groups of participants are included: 1) Patients with a previous positive patch test to oxidized R-Limonene, 2) patients with a previous doubtful patch test to oxidized R-limonene and 3) healthy controls with no contact allergy to oxidized R-limonene